|
|
|
| From Fermentation To Vaccination | Webinar | MilliporeSigma | Non-animal-origin squalene is gaining momentum in vaccine adjuvants. See how fermentation-derived squalene delivers comparable performance, strong stability, and regulatory alignment. |
|
|
|
|
By Mathini Ilancheran, Beroe Inc. | Beginning July 31, 2026, a U.S. pharmaceutical tariff will apply to patented products and their APIs, beginning with large companies. Beroe Inc.'s Mathini Ilancheran breaks down the tariff's impact, explores its risks, and proposes five procurement strategies to addressing them. | |
|
|
|
By Kishore Hotha, Ph.D., Dr. Hotha’s Life Sciences LLC | The warning letter, issued to Purolea Cosmetics Lab, describes a manufacturer that used AI agents to generate drug product specifications and more. Here's why the outsourced pharma industry should take note. | |
|
|
|
By Partha Anbil, MIT Sloan Life Sciences Industry Advisor | First came excitement over the looming patent cliff. Then, FDA and EMA took big swings at what many have called redundant work. Combined, they make a more attractive environment for biosimilar developers. | |
|
|
